Open AccessThe Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2 1-180 ) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
Author(s) -
Sergio Utrilla-Trigo,
Luís Jiménez-Cabello,
Eva Calvo-Pinilla,
Alejandro Marín-López,
Gema Lorenzo,
P.J. Sánchez-Cordón,
Sandra Moreno,
Julio Benavides,
Sarah C. Gilbert,
Aitor Nogales,
Javier Ortego
Publication year - 2022
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.01614-21
Subject(s) - biology , virology , diva , vaccination , virus , viremia , modified vaccinia ankara , immunogenicity , serotype , vaccinia , immunology , antigen , recombinant dna , genetics , gene
Current BTV vaccines are effective but they do not allow to distinguish between vaccinated and infected animals (DIVA strategy) and are serotype specific. In this work we have develop a DIVA multiserotype vaccination strategy based on adenoviral (ChAdOx1) and MVA vaccine vectors, the most widely used in current phase I and II clinical trials, and the conserved nonstructural BTV proteins NS1 and NS2. This immunization strategy solves the major drawbacks of the current marketed vaccines.